Literature DB >> 29044540

Factors affecting hospital length of stay following pelvic exenteration surgery.

Ying Guo1, Eugene Chang2, Mehtap Bozkurt3, Minjeong Park4, Diane Liu4, Jack B Fu1.   

Abstract

BACKGROUND AND OBJECTIVES: Total pelvic exenteration are performed in patients with locally advanced or recurrent pelvic malignances. Many patients have prolong hospital length of stay (LOS), but risk factors are not clearly identified.
METHODS: From 2002 through 2012, 100 consecutive patients undergoing pelvic exenteration were retrospectively reviewed. A general linear model was used to examine risk factors for prolonged hospital LOS.
RESULTS: Among the 100 patients, 51 had gastrointestinal cancer, 14 had genitourinary cancer, 31 had gynecologic cancer, and 4 had sarcoma. Perioperative complications included infection (n = 44), anastomotic leak/fistula (n = 6), wound or flap dehiscence (n = 11), and ileus or bowel obstruction (n = 30). The median (Interquartile range (IQR)) hospital LOS was 15 days (10-21.5 days). On multivariate regression analysis, hospital LOS was significantly prolonged by underweight status, genitourinary cancer or sarcoma diagnosis, ≥2 infections, anastomotic leak/fistula, requiring rehabilitation consult and admission, and ≥2 consultations (P = 0.05).
CONCLUSION: In patients undergoing pelvic exenteration, prolonged hospital LOS is associated with underweight status, genitourinary cancer or sarcoma diagnosis, more than one infection, anastomotic leak/fistula, requiring rehabilitation consult and admission, and more than one consultation. Further study is needed to assess whether minimizing these risk factors can improve hospital LOS in these patients.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  cancer; hospital length of stay; pelvic exenteration

Mesh:

Year:  2017        PMID: 29044540      PMCID: PMC5854513          DOI: 10.1002/jso.24878

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  28 in total

Review 1.  Evolution of pelvic exenteration.

Authors:  Marvin J Lopez; Limaris Barrios
Journal:  Surg Oncol Clin N Am       Date:  2005-07       Impact factor: 3.495

2.  Pelvic exenteration for the treatment of locally advanced colorectal and bladder malignancies in the modern era.

Authors:  Paul J Speicher; Ryan S Turley; Jason L Sloane; Christopher R Mantyh; John Migaly
Journal:  J Gastrointest Surg       Date:  2013-11-08       Impact factor: 3.452

3.  Survival after pelvic exenteration for T4 rectal cancer.

Authors:  M Kusters; K K S Austin; M J Solomon; P J Lee; G A P Nieuwenhuijzen; H J T Rutten
Journal:  Br J Surg       Date:  2015-01       Impact factor: 6.939

4.  Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma.

Authors:  Christopher J Gannon; Jonathan S Zager; George J Chang; Barry W Feig; Christopher G Wood; John M Skibber; Miguel A Rodriguez-Bigas
Journal:  Ann Surg Oncol       Date:  2007-04-04       Impact factor: 5.344

5.  Long-term clinical outcome of pelvic exenteration in patients with advanced gynecological malignancies.

Authors:  Christina Fotopoulou; Ulf Neumann; Robert Kraetschell; Joerg C Schefold; Henning Weidemann; Werner Lichtenegger; Jalid Sehouli
Journal:  J Surg Oncol       Date:  2010-05-01       Impact factor: 3.454

6.  Outcomes of pelvic exenteration for locally advanced primary rectal cancer: Overall survival and quality of life.

Authors:  A J Quyn; K K S Austin; J M Young; T Badgery-Parker; L M Masya; R Roberts; M J Solomon
Journal:  Eur J Surg Oncol       Date:  2016-02-24       Impact factor: 4.424

7.  Pelvic exenteration: impact of age on surgical and oncologic outcomes.

Authors:  Marilyn Huang; David A Iglesias; Shannon N Westin; Bryan Fellman; Diana Urbauer; Kathleen M Schmeler; Michael Frumovitz; Pedro T Ramirez; Pamela T Soliman
Journal:  Gynecol Oncol       Date:  2013-11-18       Impact factor: 5.482

8.  Clinical algorithms for the diagnosis and management of urological leaks following pelvic exenteration.

Authors:  K G M Brown; C E Koh; A Vasilaras; D Eisinger; M J Solomon
Journal:  Eur J Surg Oncol       Date:  2013-10-18       Impact factor: 4.424

9.  Pelvic exenteration: ten-year experience at the European Institute of Oncology in Milan.

Authors:  Angelo Maggioni; Giovanni Roviglione; Fabio Landoni; Vanna Zanagnolo; Michele Peiretti; Nicoletta Colombo; Luca Bocciolone; Roberto Biffi; Lucas Minig; C Paul Morrow
Journal:  Gynecol Oncol       Date:  2009-05-02       Impact factor: 5.482

10.  Total pelvic exenteration for primary and recurrent malignancies.

Authors:  F T J Ferenschild; M Vermaas; C Verhoef; A C Ansink; W J Kirkels; A M M Eggermont; J H W de Wilt
Journal:  World J Surg       Date:  2009-07       Impact factor: 3.352

View more
  1 in total

1.  Surgical removal of giant pelvic liposarcoma after preoperative transcatheter arterial embolization.

Authors:  Yuto Maeda; Yuji Miyamoto; Yukiharu Hiyoshi; Kojiro Eto; Masaaki Iwatsuki; Shiro Iwagami; Yoshifumi Baba; Naoya Yoshida; Hideo Baba
Journal:  Int Cancer Conf J       Date:  2022-08-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.